Abstract
Oncolytic adenoviral vectors are currently being developed as biologic anticancer agents. Coupling the lytic function of an oncolytic adenovirus (Ad) with its ability as a transgene delivery system represents a powerful extension of this methodology. A clear advantage is the amplification of a therapeutic gene, as replicating vectors would be able to infect and deliver the gene of interest to neighboring cells. Granulocyte–macrophage colony-stimulating factor (GM-CSF) is one of the most potent stimulators of a specific and long-lasting antitumor immunity and its important role in the maturation of antigen-presenting cells to induce T-cell activation has been well documented. Similarly, the B7 family has also been shown to play an integral role in mediating an antitumor response. Most tumor cells, however, lack the expression of these costimulatory molecules on their surface, thus escaping immune system recognition. To increase the antitumor effect of an oncolytic Ad, we have generated an E1B 55 kDa-deleted oncolytic adenoviral vector, YKL-GB, that expresses both GM-CSF and B7-1. The therapeutic efficacy of YKL-GB Ad was evaluated in immunocompetent mice bearing murine melanoma B16-F10 tumors. Significant inhibition of tumor growth was seen in mice treated with YKL-GB compared to those treated with the analogous vector, YKL-1. Moreover, YKL-GB oncolytic Ad demonstrated enhanced antitumor activity and higher incidences of tumor regression compared to a replication-incompetent Ad, dl-GB, which coexpresses GM-CSF and B7-1. Localized GM-CSF and B7-1 gene transfer also conferred long-lasting immunity against a tumor re-challenge. To establish that the observed antitumor effect is associated with the generation of a tumor-specific immune response, we carried out interferon-γ enzyme-linked immune spot assay. We observed that YKL-GB induced significantly higher immune cell activation than YKL-1. Furthermore, immunohistochemical studies demonstrated robust dendritic cells and CD4+/CD8+ T-cell infiltration in these mice compared to the YKL-1-treated groups. In agreement with these results, splenocytes from tumor-bearing mice treated with YKL-GB expressed high levels of the costimulatory and activation molecules. These findings demonstrate the effectiveness of enhancing the immune response against tumors with an oncolytic Ad expressing both GM-CSF and B7-1 and provide a potential therapeutic strategy for the management of neoplasia.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H . Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus- and retrovirus-mediated genetic transduction. J Cancer Res Clin Oncol 1995; 121: 587–592.
Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539–3543.
Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP . Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med 1999; 190: 125–133.
Curiel-Lewandrowski C, Mahnke K, Labeur M, Roters B, Schmidt W, Granstein RD et al. Transfection of immature murine bone marrow-derived dendritic cells with the granulocyte-macrophage colony-stimulating factor gene potently enhances their in vivo antigen-presenting capacity. J Immunol 1999; 163: 174–183.
Hornell TM, Beresford GW, Bushey A, Boss JM, Mellins ED . Regulation of the class II MHC pathway in primary human monocytes by granulocyte-macrophage colony-stimulating factor. J Immunol 2003; 171: 2374–2383.
Pan PY, Li Y, Li Q, Gu P, Martinet O, Thung S et al. In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol Immunother 2004; 53: 17–25.
Arca MJ, Krauss JC, Aruga A, Cameron MJ, Shu S, Chang AE . Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor. Cancer Gene Ther 1996; 3: 39–47.
Arca MJ, Krauss JC, Strome SE, Cameron MJ, Chang AE . Diverse manifestations of tumorigenicity and immunogenicity displayed by the poorly immunogenic B16-BL6 melanoma transduced with cytokine genes. Cancer Immunol Immunother 1996; 42: 237–245.
Fagerberg J . Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy. Med Oncol 1996; 13: 155–160.
Lumsden JM, Prasad SJ, Peach RJ, Ronchese F . The effects of B7-dependent costimulation on T cell division and survival in vivo and in vitro are dependent on antigen concentration. Eur J Immunol 2003; 33: 2074–2082.
Judge TA, Tang A, Turka LA . Immunosuppression through blockade of CD28:B7-mediated costimulatory signals. Immunol Res 1996; 15: 38–49.
Fagnoni FF, Takamizawa M, Godfrey WR, Rivas A, Azuma M, Okumura K et al. Role of B70/B7-2 in CD4+ T-cell immune responses induced by dendritic cells. Immunology 1995; 85: 467–474.
Hui K, Grosveld F, Festenstein H . Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature 1984; 311: 750–752.
Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M . Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 1985; 315: 301–305.
Larsen CP, Ritchie SC, Hendrix R, Linsley PS, Hathcock KS, Hodes RJ et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 1994; 152: 5208–5219.
Granucci F, Girolomoni G, Lutz MB, Ricciardi-Castagnoli P . Recombinant GM-CSF induces cytokine production in mouse dendritic cell clones. Adv Exp Med Biol 1995; 378: 31–34.
Grabbe S, Beissert S, Schwarz T, Granstein RD . Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol Today 1995; 16: 117–121.
Haddad D, Ramprakash J, Sedegah M, Charoenvit Y, Baumgartner R, Kumar S et al. Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles. J Immunol 2000; 165: 3772–3781.
Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G . Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 2000; 60: 3239–3246.
Portella G, Scala S, Vitagliano D, Vecchio G, Fusco A . ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 2002; 87: 2525–2531.
Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–376.
Khuri FR, Nemunaitis J, Ganly I, Arseneau J, Tannock IF, Romel L et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879–885.
Armstrong CA, Botella R, Galloway TH, Murray N, Kramp JM, Song IS et al. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 1996; 56: 2191–2198.
Cella M, Sallusto F, Lanzavecchia A . Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 1997; 9: 10–16.
Steinman RM . The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271–296.
Labeur MS, Roters B, Pers B, Mehling A, Luger TA, Schwarz T et al. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J Immunol 1999; 162: 168–175.
Lanzavecchia A . Dendritic cell maturation and generation of immune responses. Haematologica 1999; 84 (Suppl EHA-4): 23–25.
Gunji Y, Tagawa M, Matsubara H, Takenaga K, Shimada H, Kondo F et al. Antitumor effect induced by the expression of granulocyte–macrophage-colony stimulating factor gene in murine colon carcinoma cells. Cancer Lett 1996; 101: 257–261.
Yu JS, Burwick JA, Dranoff G, Breakefield XO . Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 1997; 8: 1065–1072.
Mueller DL, Jenkins MK, Schwartz RH . Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu Rev Immunol 1989; 7: 445–480.
Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996; 183: 87–97.
Townsend SE, Allison JP . Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993; 259: 368–370.
Lee CT, Wu S, Ciernik IF, Chen H, Nadaf-Rahrov S, Gabrilovich D et al. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 1997; 8: 187–193.
Stam AG, Santegoets SJ, Westers TM, Sombroek CC, Janssen JJ, Tillman BW et al. CD40-targeted adenoviral GM-CSF gene transfer enhances and prolongs the maturation of human CML-derived dendritic cells upon cytokine deprivation. Br J Cancer 2003; 89: 1162–1165.
Yun CO, Kim E, Koo T, Kim H, Lee YS, Kim JH . ADP-overexpressing adenovirus elicits enhanced cytopathic effect by induction of apoptosis. Cancer Gene Ther 2005; 12: 61–71.
Lee H, Kim J, Lee B, Chang JW, Ahn J, Park JO et al. Oncolytic potential of E1B 55 kDa-deleted YKL-1 recombinant adenovirus: correlation with p53 functional status. Int J Cancer 2000; 88: 454–463.
Acknowledgements
We thank all of our colleagues at Yonsei Cancer Center, Seoul, Korea who have contributed to these studies. This work was supported by grants from the Ministry of Commerce, Industry and Energy, Republic of Korea (990-14-05-00008131, Dr C-O Yun) and KOSEF through National Core Research Center for Nanomedical Technology (R15-2004-024-02001-0, Dr C-O Yun and Dr J-H Kim). Kyung-Ju Choi, Young-Sook Lee and Jaesung Kim are graduate students sponsored by the Brain Korea 21 Project for Medical Science, Yonsei University, Seoul, South Korea.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Choi, KJ., Kim, JH., Lee, YS. et al. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect. Gene Ther 13, 1010–1020 (2006). https://doi.org/10.1038/sj.gt.3302759
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3302759
Keywords
This article is cited by
-
Personalizing Oncolytic Immunovirotherapy Approaches
Molecular Diagnosis & Therapy (2024)
-
GM-CSF elicits antibodies to tumor-associated proteins when used as a prostate cancer vaccine adjuvant
Cancer Immunology, Immunotherapy (2022)
-
Optimizing oncolytic virotherapy in cancer treatment
Nature Reviews Drug Discovery (2019)
-
Oncolytic viruses: adenoviruses
Virus Genes (2017)
-
Non-viral immune electrogene therapy induces potent antitumour responses and has a curative effect in murine colon adenocarcinoma and melanoma cancer models
Gene Therapy (2015)